

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
| Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
| Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
| Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
| Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
| Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
| NS-398 |
++
COX-2, IC50: 3.8 μM |
95% | |||||||||||||||||
| Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
| Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
| Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
| Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
| Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects. |
| Concentration | Treated Time | Description | References | |
| primary mature BAT adipocytes | 15 μM | 5 days | AO significantly increased the activities of mitochondrial complexes I and IV and decreased ATP levels, suggesting that AO promotes energy expenditure by activating UCP1-mediated mitochondrial respiration uncoupling. | Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840 |
| Primary BAT adipocytes | 15 μM | 24 h | To study the effect of AO on oxidative stress and mitochondrial function in primary BAT adipocytes, AO reduced oxidative stress and inhibited mPTP opening. | Chin Med. 2025 Mar 25;20(1):41 |
| AML12 cells | 15 μM | 24 h | To investigate the effect of AO on inflammation in AML12 cells, AO reduced inflammation in AML12 cells by inhibiting mtDNA release from BAT cells. | Chin Med. 2025 Mar 25;20(1):41 |
| HepG2 cells | 10-600 µM | 48 h | To evaluate the inhibitory effect of AO on liver cancer cell activity, the results showed that AO significantly inhibited the proliferation of SK-Hep1 and HepG2 cells. | Int J Oncol. 2024 Oct;65(4):92 |
| HepG2 cells | 25 μM | 3 and 5 h | AO effectively promoted autophagy flux in HepG2 cells, as evidenced by a sustained increase in the number of red fluorescent puncta (autolysosomes). | Front Pharmacol. 2022 Jan 11;12:826628 |
| Mouse primary hepatocytes (MPHs) | 12.5, 25, 50 μM | 24 h | AO significantly alleviated OAPA-induced lipid accumulation in hepatocytes, dose-dependently reduced the number and size of lipid droplets, and decreased intracellular TG content. | Front Pharmacol. 2022 Jan 11;12:826628 |
| RAW264.7 cells | 6.25-50 μM | 24 h | To investigate the anti-inflammatory effects of Aurantio-obtusin on LPS-induced RAW264.7 cells. Results showed that Aurantio-obtusin significantly inhibited the production of NO, PGE2, and reduced the protein expression of COX-2, TNF-α, and IL-6. | Molecules. 2018 Nov 27;23(12):3093 |
| Human renal glomerular endothelial cells (HRGECs) | 50, 100, 200 µM | 48 h | To assess the cytotoxic effects of AO on HRGECs. AO caused decreased cell viability, increased LDH leakage, increased secretion of inflammatory cytokines (IL-6, TNF-α, TGF-β1, MCP-1), and decreased ZO-1 expression. | Nutrients. 2022 Nov 2;14(21):4615 |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6J mice | HFHS diet-induced obese mouse model | Oral gavage | 10 mg/kg | Once daily for 4 weeks | AO significantly increased the weight of BAT and accelerated energy expenditure to protect the weight increase in the obese mice. | Acta Pharmacol Sin. 2023 Sep;44(9):1826-1840 |
| C57BL/6J mice | High-fat diet and glucose-fructose water (HFSW)-induced NAFLD mouse model | Oral gavage | 5, 10, 15 mg/kg | Once daily for 4 weeks | AO significantly alleviated HFSW-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC content, and improved liver histology. | Front Pharmacol. 2022 Jan 11;12:826628 |
| Sprague-Dawley (SD) rats | Hepatotoxicity model | Oral | 4, 40, and 200 mg/kg | Once daily for 28 days | To study the hepatotoxic effects of Aurantio-obtusin in rats and identify potential biomarkers in urine. Results showed that 23 metabolites were identified as potential biomarkers, with 10 up-regulated and 13 down-regulated. | Front Pharmacol. 2020 Aug 12;11:1237 |
| C57BL/6J mice | HFHS diet-induced obesity model | Oral | 10 mg/kg | Once daily for 4 weeks | To investigate the effect of AO on BAT function and hepatic inflammation in obese mice, AO improved mitochondrial function in BAT and reduced hepatic inflammation. | Chin Med. 2025 Mar 25;20(1):41 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.03mL 0.61mL 0.30mL |
15.14mL 3.03mL 1.51mL |
30.28mL 6.06mL 3.03mL |
|
| CAS号 | 67979-25-3 |
| 分子式 | C17H14O7 |
| 分子量 | 330.29 |
| SMILES Code | O=C1C2=C(C=C(C)C(O)=C2OC)C(C3=CC(O)=C(OC)C(O)=C13)=O |
| MDL No. | MFCD13194886 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | RNXZPKOEJUFJON-UHFFFAOYSA-N |
| Pubchem ID | 155011 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 25 mg/mL(75.69 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1